MDPI and ACS Style
Imran, M.; Arora, M.K.; Chaudhary, A.; Khan, S.A.; Kamal, M.; Alshammari, M.M.; Alharbi, R.M.; Althomali, N.A.; Alzimam, I.M.; Alshammari, A.A.;
et al. MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. Biomedicines 2022, 10, 2793.
https://doi.org/10.3390/biomedicines10112793
AMA Style
Imran M, Arora MK, Chaudhary A, Khan SA, Kamal M, Alshammari MM, Alharbi RM, Althomali NA, Alzimam IM, Alshammari AA,
et al. MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature. Biomedicines. 2022; 10(11):2793.
https://doi.org/10.3390/biomedicines10112793
Chicago/Turabian Style
Imran, Mohd., Mandeep Kumar Arora, Anurag Chaudhary, Shah Alam Khan, Mehnaz Kamal, Manal Mutlaq Alshammari, Raghad Mohammad Alharbi, Nuha Abdullah Althomali, Ibrahim Mohammed Alzimam, Abdullah Ayed Alshammari,
and et al. 2022. "MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature" Biomedicines 10, no. 11: 2793.
https://doi.org/10.3390/biomedicines10112793